Roche/GSK Once-Quarterly Boniva Injection Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
Injectable ibandronate could improve patient compliance with osteoporosis therapy because it is administered by a healthcare professional, firms say.
You may also be interested in...
Novartis On The Move: Firm Files Tasigna, Aclasta Ahead Of Schedule
Novartis also announces the roll-out of an expanded access program for Tasigna during its annual pipeline update.
Novartis On The Move: Firm Files Tasigna, Aclasta Ahead Of Schedule
Novartis also announces the roll-out of an expanded access program for Tasigna during its annual pipeline update.
Roche Plans Boniva Ad Changes To Energize “Static” Script Growth
Swiss drug maker’s new strategy for the osteoporosis therapy will include Fosamax comparison data, new spokesperson.